Ferring International Center SA - Company Profile
Powered by 
All the sales intelligence you need on Ferring International Center SA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ferring International Center SA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ferring International Center SA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ferring International Center SA (Ferring), a subsidiary of Ferring Holding SA, is a research-driven, specialty biopharmaceutical company. Its primary activities include research and development in reproductive medicine, women's health, gastroenterology and urology. Ferring's product portfolio includes treatments for reproductive medicine and maternal health, urology and uro-oncology, gastroenterology and microbiome, endocrinology and orthopedics. Ferring's products are used by patients seeking treatments in the areas of reproductive health, gastroenterology, and urology, among others. The company has a global presence with manufacturing sites and R&D centers in countries such as China, Japan, India, Denmark, Brazil, Israel, the UK and the US. Ferring Pharmaceuticals is headquartered in Saint-Prex, Switzerland.
Headquarters
Switzerland
Address
Ch. de la Vergognausaz 50, Saint-Prex, Waadt, 1162
Website
www.ferring.com
Telephone
41 58 3010000
Industry
Pharmaceuticals and Healthcare
Ferring International Center SA premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Endocrinology | Drug Discovery Partnering | Menopur |
| Orthopedics | Late-Stage Collaborations | Endometrin/ Lutinus |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In April, the company along with Astellas/Pfizer Alliance signed a partnership with the Bladder Cancer Advocacy Network for its 2025 Walks to End Bladder Cancer. |
| 2025 | Corporate Changes/Expansions | In April, the company announced the US Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in New Jersey, for its intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg). |
| 2024 | Corporate Changes/Expansions | In October, the company announced the opening of a state-of-the-art global manufacturing hub in Finland. |
Competitor Comparison
| Key Parameters | Ferring International Center SA | Max Zeller Soehne AG | Med Discovery SA | Mepha Pharma AG | Release Therapeutics |
|---|---|---|---|---|---|
| Headquarters | Switzerland | Switzerland | Switzerland | Switzerland | Switzerland |
| City | Saint-Prex | Romanshorn | Epalinges | Basel | Geneva |
| State/Province | Waadt | Thurgau | Waadt | Basel-Stadt | - |
| No. of Employees | - | 150 | - | 190 | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jean-Frederic Paulsen | Chairman; Chief Executive Officer | Executive Board | 2026 | - |
| Dominic Moorhead | Executive Vice President; Chief Financial Officer | Senior Management | 2017 | - |
| Christelle Beneteau | Chief People Officer; Senior Vice President | Senior Management | 2021 | - |
| Cyril Grandchamp-Desraux | Chief Operations Officer; Executive Vice President | Senior Management | 2024 | - |
| Andre Overmeyer | Chief Technical Operations Officer; Executive Vice President | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer